Zofran Lawsuit News: Status of Federal Birth Defects Cases to Be Discussed During July Status Conference, Bernstein Liebhard LLP Reports

(PRLeap.com) July 20, 2016 – The federal court overseeing hundreds of Zofran birth defects lawsuits (http://www.rxinjuryhelp.com/zofran/birth-defects/) is scheduled to convene its July Status Conference today at 1:30 p.m., at which time the progress of the litigation will be discussed. According to a Joint Agenda submitted to the U.S. District Court, District of Massachusetts, on June 18th, the Court will also hear arguments on GlaxoSmithKline’s motions for sequenced discovery and a protective order concerning certain plaintiffs’ deposition notices. (In Re Zofran Products Liability Litigation – MDL 2657)

“Our Firm is representing clients who have alleged that the use of Zofran during pregnancy caused their child to develop serious heart defects and other congenital abnormalities. We are looking forward to today’s conference, as the matters addressed during the proceeding may prove relevant to our clients’ claims,” says Sandy A. Liebhard, a partner at Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm continues to offer free Zofran lawsuit reviews to families whose children may have been harmed by this medication.

Zofran and Birth Defects
Court documents indicate that at least 270 Zofran lawsuits have been filed in the District of Massachusetts. Plaintiffs allege that GlaxoSmithKline concealed evidence linking Zofran to birth defects, and failed to provide doctors and patients with adequate warnings about this risk. They further claim that the company aggressively promoted the use of Zofran as a treatment for pregnancy-related nausea and vomiting, even though the medication has never been approved by the U.S. Food & Drug Administration (FDA) for this purpose.

The FDA has categorized Zofran as a Pregnancy Category C medication, which indicates that its effects on a developing pregnancy have not been well studied. The medication is currently only approved to treat nausea and vomiting experienced by post-op surgery patients or those undergoing certain cancer therapies. In spite of this, a recent analysis published in the American Journal of Obstetrics and Gynecology reported that around 1 million expectant mothers annually are prescribed Zofran or a generic equivalent to treat pregnancy-related nausea and vomiting.

Among other things, Zofran lawsuits claim that GlaxoSmithKline was aware of animal studies conducted as early as the 1980s that suggested the drug’s active ingredient could cross the placental barrier in pregnant mammals. In 2006, a study involving 41 pregnancies confirmed the placental transfer of Zofran in humans. The complaints also point out that in 2012, Glaxo entered into a $3 billion drug marketing settlement with the U.S. Department of Justice that, among other things, resolved claims that the company had illegally promoted Zofran for the off-label treatment of morning sickness.

Children who allegedly suffered serious birth defects due to their mothers’ use of Zofran during the first trimester of pregnancy may be entitled to compensation from GlaxoSmithKline. To discuss filing a Zofran lawsuit with a member of our legal team, please visit Bernstein Liebhard LLP’s website, or call the Firm directly at 800-511-5092.

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3.5 billion on behalf of our clients. The Firm was named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list for a dozen consecutive years.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092

ATTORNEY ADVERTISING. © 2016 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Sandy A. Liebhard, Esq.
Bernstein Liebhard LLP
info (at)consumerinjurylawyers(dot)com
http://www.rxinjuryhelp.com/
https://plus.google.com/115936073311125306742?rel=author

GET IN TOUCH
Sandy Liebhard
RX Injury Help
800-511-5092
http://www.rxinjuryhelp.com/

You can see the original version and more on PRLeap here: http://www.prleap.com/pr/247922/zofran-lawsuit-news-status-of-federal-birth

Release ID: 247922

Source: PRLeap